Dow Jones
39.431,51 -81,29 (-0,21%) Nasdaq
16.388,24 +47,34 (+0,29%) Nikkei 225
38.156,31 -23,15 (-0,06%) EUR/USD
1,0791 -0,0002 (-0,02%) Bitcoin EUR
57.836,38 +1.189,43 (+2,10%) CMC Crypto 200
1.285,14 +24,94 (+1,98%)
CLLS May 2024 5.000 put
| Chiusura precedente | 2,0000 |
| Aperto | 2,0000 |
| Denaro | 2,1500 |
| Lettera | 2,7000 |
| Prezzo d'esercizio | 5,00 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 2,0000 - 2,0000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 2 |
GlobeNewswireCellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)
NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy – Methods & Clinical Development, demonstrating the efficacy of its TALEN-mediated gene correction of mutated PIK3CD gene in APDS1 T-cells. The research work described in this articl
- GlobeNewswire
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority)PARIS, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights09/30/202355,583,76861,519,946 About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherap
- GlobeNewswire
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data on MUC1-CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023), that will take place on November 1-5, 2023 at San
